[1]
Ciapponi, A. et al. 2024. Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER2 positive breast cancer: systematic review and network meta-analysis. Revista Peruana de Medicina Experimental y Salud Pública. 41, 1 (Mar. 2024), 7–18. DOI:https://doi.org/10.17843/rpmesp.2024.411.13351.